Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer's disease.

Autor: Zhou C; 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China., Zeng F; State Key Laboratory of Infectious Disease Vaccine Development, Xiang An Biomedicine Laboratory & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China., Yang H; 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China., Liang Z; 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China., Xu G; 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China., Li X; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. lixiao@sinap.ac.cn., Liu X; Department of Nuclear Medicine, Pudong Hospital, Fudan University, Shanghai, 201399, China. xingdliu@fudan.edu.cn., Yang J; 411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China. yj_scu@163.com.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Aug; Vol. 51 (10), pp. 2953-2969. Date of Electronic Publication: 2024 Mar 19.
DOI: 10.1007/s00259-024-06690-1
Abstrakt: Background: Near-infrared II theranostic agents have gained great momentum in the research field of AD owing to the appealing advantages. Recently, an array of activatable NIR-II fluorescence probes has been developed to specifically monitor pathological targets of AD. Furthermore, various NIR-II-mediated nanomaterials with desirable photothermal and photodynamic properties have demonstrated favorable outcomes in the management of AD.
Methods: We summerized amounts of references and focused on small-molecule probes, nanomaterials, photothermal therapy, and photodynamic therapy based on NIR-II fluorescent imaging for the diagnosis and treatment in AD. In addition, design strategies for NIR-II-triggered theranostics targeting AD are presented, and some prospects are also addressed.
Results: NIR-II theranostic agents including small molecular probes and nanoparticles have received the increasing attention for biomedical applications. Meanwhile, most of the theranostic agents exhibited the promising results in animal studies. To our surprise, the multifunctional nanoplatforms also show a great potential in the diagnosis and treatment of AD.
Conclusions: Although NIR-II theranostic agents showed the great potential in diagnosis and treatment of AD, there are still many challenges: 1) Faborable NIR-II fluorohpores are still lacking; 2) Biocompatibility, bioseurity and dosage of NIR-II theranostic agents should be further revealed; 3) New equipment and software associated with NIR-II imaging system should be explored.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: